Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis

British Journal of Clinical Pharmacology

Volumn 81, Issue 5, 2016, Pages 958-970

  Budde, Klemens ^a   Zonnenberg, Bernard A ^b   Frost, Michael ^c   Cheung, Wing ^d   Urva, Shweta ^d   Brechenmacher, Thomas ^e   Stein, Karen ^d   Chen, David ^d   Kingswood, John Christopher ^f   Bissler, John J ^g  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MINNESOTA EPILEPSY GROUP   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e NOVARTIS PHARMA K K   (Japan)

^f ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^g UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

angiomyolipoma; biomarkers; collagen IV; lymphangioleiomyomatosis; tuberous sclerosis complex; VEGF D

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN TYPE 4; EVEROLIMUS; PLACEBO; VASCULOTROPIN A; VASCULOTROPIN D; ANTINEOPLASTIC AGENT; VEGFA PROTEIN, HUMAN; VEGFD PROTEIN, HUMAN;

ADULT; ANGIOGENESIS; ANGIOMYOLIPOMA; ARTICLE; BLOOD SAMPLING; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EXPOSURE; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KIDNEY TUMOR; LYMPHANGIOLEIOMYOMATOSIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TUBEROUS SCLEROSIS; TUMOR GROWTH; BLOOD; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DOSE RESPONSE; KIDNEY NEOPLASMS; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANGIOMYOLIPOMA; ANTINEOPLASTIC AGENTS; COLLAGEN TYPE IV; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; EVEROLIMUS; HUMANS; KIDNEY NEOPLASMS; LYMPHANGIOLEIOMYOMATOSIS; TUBEROUS SCLEROSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR D;

EID: 84959563384     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12834     Document Type: Article

References (36)

1. Huang J, Manning BD,. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 2008; 412: 179-90.
2. Budde K, Gaedeke J,. Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition. Am J Kidney Dis 2012; 59: 276-83.
3. Crino PB, Nathanson KL, Henske EP,. The tuberous sclerosis complex. N Engl J Med 2006; 355: 1345-56.
4. Curatolo P, Bombardieri R, Jozwiak S,. Tuberous sclerosis. Lancet 2008; 372: 657-68.
5. Franz DN, Bissler JJ, McCormack FX,. Tuberous sclerosis complex: neurological, renal and pulmonary manifestations. Neuropediatrics 2010; 41: 199-208.
6. Dixon BP, Hulbert JC, Bissler JJ,. Tuberous sclerosis complex renal disease. Nephron Exp Nephrol 2011; 118: e15-20.
7. Siroky BJ, Yin H, Dixon BP, Reichert RJ, Hellmann AR, Ramkumar T, Tsuchihashi Z, Bunni M, Dillon J, Bell PD, Sampson JR, Bissler JJ,. Evidence for pericyte origin of TSC-associated renal angiomyolipomas and implications for angiotensin receptor inhibition therapy. Am J Physiol Renal Physiol 2014; 307: F560-70.
8. Yamakado K, Tanaka N, Nakagawa T, Kobayashi S, Yanagawa M, Takeda K,. Renal angiomyolipoma: relationships between tumor size, aneurysm formation, and rupture. Radiol 2002; 225: 78-82.
9. Eble JN,. Angiomyolipoma of kidney. Semin Diagn Pathol 1998; 15: 21-40.
10. Bissler JJ, Kingswood JC,. Renal angiomyolipomata. Kidney Int 2004; 66: 924-34.
11. Cudzilo CJ, Szczesniak RD, Brody AS, Rattan MS, Krueger DA, Bissler JJ, Franz DN, McCormack FX, Young LR,. Lymphangioleiomyomatosis screening in women with tuberous sclerosis. Chest 2013; 144: 578-85.
12. McCormack FX,. Lymphangioleiomyomatosis: a clinical update. Chest 2008; 133: 507-16.
13. Franz DN, Brody A, Meyer C, Leonard J, Chuck G, Dabora S, Sethuraman G, Colby TV, Kwiatkowski DJ, McCormack FX,. Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med 2001; 164: 661-8.
14. Costello LC, Hartman TE, Ryu JH,. High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. Mayo Clin Proc 2000; 75: 591-4.
15. Carsillo T, Astrinidis A, Henske EP,. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A 2000; 97: 6085-90.
16. Yeoh ZW, Navaratnam V, Bhatt R, McCafferty I, Hubbard RB, Johnson SR,. Natural history of angiomyolipoma in lymphangioleiomyomatosis: implications for screening and surveillance. Orphanet J Rare Dis 2014; 9: 151.
17. El-Hashemite N, Walker V, Zhang H, Kwiatkowski DJ,. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res 2003; 63: 5173-7.
18. Dvorak HF,. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368-80.
19. Seyama K, Kumasaka T, Souma S, Sato T, Kurihara M, Mitani K, Tominaga S, Fukuchi Y,. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol 2006; 4: 143-52.
20. Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, Whittemore VH, Chen D, Sahmoud T, Shah G, Lincy J, Lebwohl D, Budde K,. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013; 381: 817-24.
21. Dabora SL, Franz DN, Ashwal S, Sagalowsky A, DiMario FJ Jr, Miles D, Cutler D, Krueger D, Uppot RN, Rabenou R, Camposano S, Paolini J, Fennessy F, Lee N, Woodrum C, Manola J, Garber J, Thiele EA,. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF-D levels decrease. PLoS One 2011; 6: e23379.
22. Xu KF, Zhang P, Tian X, Ma A, Li X, Zhou J, Zeng N, Gui YS, Guo Z, Feng R, Zhang W, Sun W, Cai B,. The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM). Respir Med 2013; 107: 263-8.
23. Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Souter M, Nonomura N, Brakemeier S, de Vries PJ, Berkowitz N, Segal S, Anak O, Peyrard S, Budde K,. Everolimus for renal angiomyolipoma associated with tuberous sclerosis complex (TSC): EXIST-2 ~ 3-year follow-up. Poster presented at 29th Annual Congress of the European Association of Urology; April 11-15, 2014; Stockholm, Sweden.
24. Kirchner GI, Meier-Wiedenbach I, Manns MP,. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004; 43: 83-95.
25. US Department of Health and Human Services. Guidance for Industry. Bioanalytical Method Validation. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf. May 2001. Accessed October 30, 2015.
26. Peveling-Oberhag J, Zeuzem S, Yong WP, Kunz T, Paquet T, Bouillaud E, Urva S, Anak O, Sellami D, Kobalava Z,. Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study. Clin.Ther 2013; 35: 215-25.
27. Xu B, Wu Y, Shen L, Ye D, Jappe A, Cherfi A, Wang H, Yuan R,. Two dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors. J Hematol Oncol 2011; 4: 3.
28. O'Donnell A, Faivre S, Burris HA III, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I,. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008; 26: 1588-95.
29. Okamoto I, Doi T, Ohtsu A, Miyazaki M, Tsuya A, Kurei K, Kobayashi K, Nakagawa K,. Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors. Jpn J Clin Oncol 2010; 40: 17-23.
30. Jacobsen W, Serkova N, Hausen B, Morris RE, Benet LZ, Christians U,. Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD. Transplant Proc 2001; 33: 514-5.
31. Oudard S, Escudier BJ, Thompson JA, Grunwald V, Masini C, Bracarda S, Paneerselvam A, Gogov S, Chen D, Motzer RJ,. Relationship between biomarkers and everolimus efficacy in the phase III RECORD-1 trial of patients with metastatic renal cell carcinoma (mRCC). Proceedings of the American Society of Clinical Oncology Annual Meeting. J Clin Oncol 2013; 31 (suppl 6): abstract 352.
32. Franz DN, Kingswood C, Jozwiak S, Budde K, Belousova E, Sparagana S, Zonnenberg B, Frost M, Shah G, Lebrec J, Ford J, Kalfoglou C, Chen D, Bissler JJ,. Effect of everolimus on angiogenic biomarkers in patients with tuberous sclerosis complex (TSC): results from EXIST-1 and EXIST-2. Poster presented at: 48th Annual Meeting of the American Society of Clinical Oncology; June 1-5, 2012; Chicago, Illinois.
33. van der Bilt AR, Terwisscha van Scheltinga AG, Timmer-Bosscha H, Schröder CP, Pot L, Kosterink JG, van der Zee AG, Lub-de Hooge MN, de Jong S, de Vries EG, Reyners AK,. Measurement of tumor VEGF-a levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model. Clin Cancer Res 2012; 18: 6306-14.
34. Malinowska IA, Lee N, Kumar V, Thiele EA, Franz DN, Ashwal S, Sagalowsky A, Dimario FJ Jr, Cutler D, Krueger D, Camposano S, Paolini J, Dabora SL,. Similar trends in serum VEGF-D levels and kidney angiomyolipoma responses with longer duration sirolimus treatment in adults with tuberous sclerosis. PLoS One 2013; 8: e56199.
35. McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira-DaSilva AM, Lee HS, Krischer JP,. Trapnell BC, National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011; 364: 1595-606.
36. Young LR, Lee HS, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Downey GP, Swigris JJ, Taveira-DaSilva Am, Krischer JP, Trapnell BC, McCormack FX, MILES Trial Group. Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med 2013; 1: 445-52.